Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”

Documenti analoghi

• Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
  di: Lea Gerischer, et al.
  Pubblicazione: (2025)
• Prediction of Myasthenia Gravis Worsening: A Machine Learning Algorithm Using Wearables and Patient‐Reported Measures
  di: Maike Stein, et al.
  Pubblicazione: (2025)
• EEG Response to Sedation Interruption Complements Behavioral Assessment After Severe Brain Injury
  di: Charlotte Maschke, et al.
  Pubblicazione: (2025)
• Reply to Letter: “Real‐World Clinical Experience With Serum MOG and AQP4 Antibody Testing by Live Versus Fixed Cell‐Based Assay”
  di: Yana Said, et al.
  Pubblicazione: (2025)
• Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability
  di: Maike Stein, et al.
  Pubblicazione: (2025)